查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1856965

全球干细胞库市场：预测至2032年－依来源类型、库类型、服务类型、用途、最终用户和地区进行分析

Stem Cell Banking Market Forecasts to 2032 - Global Analysis By Source Type (Umbilical Cord Stem Cells, Cord Blood, Cord Tissue, Placenta, Adult Stem Cells and Other Source Types), Bank Type, Service Type, Utilization, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格
干细胞库市场预测至2032年－按来源类型、库类型、服务类型、使用率、最终用户和地理分類的全球分析

根据 Stratistics MRC 的数据，预计到 2025 年，全球干细胞库市场规模将达到 112 亿美元，到 2032 年将达到 222 亿美元，预测期内复合年增长率为 10.2%。

干细胞库是指收集、处理和保存干细胞，以备将来潜在的医疗用途。这些细胞通常来自脐带血、骨髓或脂肪组织等，具有分化成多种细胞类型和再生受损组织的独特能力。储存的干细胞可用于再生医学、器官移植以及治疗包括白血病、淋巴瘤和免疫系统疾病在内的多种疾病。干细胞库在低温下储存，为个人和家庭提供宝贵的生物资源，确保他们未来能够获得个人化治疗和先进的医疗服务。

根据国际干细胞研究协会（ISSCR）的数据，全球整体有超过7000项正在进行的干细胞临床试验，这反映了再生医学的快速研究和发展以及对品质有保证的干细胞储存日益增长的需求。

公众意识的提高和家长需求的增加

越来越多的家庭选择储存脐带血和组织，以备将来用于再生医学。教育宣传活动和产前咨询正在加深人们对干细胞在遗传和免疫疾病治疗中应用的了解。医院和妇产中心正与私人脐带血库合作，提供脐带血采集和储存服务。都市区和半都市区产科服务的可近性和需求的提高正在推动相关业务的成长。这些动态共同推动了预防医学和个人化医疗市场的扩张。

有限的已证实适应症

干细胞在治疗血液癌症和代谢紊乱方面展现出潜力，但其大部分应用仍处于实验阶段或仅限于临床试验。监管机构要求在核准新的治疗用途前进行严格的检验。由于缺乏长期获益的明确证据，父母可能不愿意投资干细胞库。新适应症缺乏标准化通讯协定也阻碍了干细胞疗法融入主流医疗体系。这些限制因素阻碍了干细胞疗法更广泛的应用和医疗保险报销。

医疗支出和私人投资增加

各国政府正资助生物样本库计画和官民合作关係，以支持再生医学的发展。创业投资和机构投资者正在扶持专注于整合冷冻保存、分析和细胞疗法的新兴企业。生育诊所和妇产科医院的扩张正在创造新的样本采集点和转诊网路。肿瘤学、神经病学和罕见疾病领域对长期生物储存的需求日益增长。这些趋势正在推动干细胞库生态系统实现可扩展且多元化的成长。

资料隐私、同意和道德透明度问题

各机构必须确保安全处理与储存样本相关的遗传和个人资讯。知情同意通讯协定必须清楚、符合年龄要求，并符合各司法管辖区的法律规定。关于样本商业化、捐赠者权利和未来用途的伦理问题需要强而有力的管治。跨境储存和合作研究正受到日益严格的监管审查。这些风险持续限制平台的信誉和相关人员的参与。

新冠疫情的影响：

疫情扰乱了产科护理和择期手术，导致干细胞采集量暂时下降。然而，疫情后的復苏重点在于将预防性护理和生物银行建设作为长期韧性的一部分。医院已恢復脐带血采集，并透过与私人血库合作扩大了获取途径。疫情期间，民众对免疫健康和再生疗法的关注度有所提高。对数位化知情同意、远端咨询和物流的投入提高了营运的连续性。这些变化正在加速干细胞库建设与儿童保健的长期融合。

预计在预测期内，脐带血干细胞部分将成为最大的细分市场。

由于脐带血干细胞易于获取、采集过程无创且具有广泛的治疗潜力，预计在预测期内，脐带血干细胞细分市场将占据最大的市场份额。脐带血含有造血干细胞，可用于治疗白血病、贫血和免疫力缺乏。脐带组织含有间质干细胞，在整形外科和神经系统疾病方面具有潜在的应用价值。脐带组织采集在分娩过程中安全无痛，因此被不同文化背景的人广泛接受。私人和公共血库正在扩大脐带血样本的冷冻保存和登记服务。这些能力正在巩固该细分市场在临床和研究应用领域的领先地位。

预计样品分析细分市场在预测期内将实现最高的复合年增长率。

预计在预测期内，样本分析领域将迎来最高的成长率，因为生物样本库和研究机构正在扩展其检测和鑑定服务。分析项目包括活性检测、 HLA型检测、污染筛检和效力测定。与人工智慧和基因组平台的整合正在推动预测建模和个人化治疗方案的发展。临床试验和细胞疗法研发管线正在推动对检验的高品质样本的需求。供应商正在提供将储存、分析和彙报相结合的配套服务。这一趋势正在促进增值生物样本库服务的成长。

比最大的地区

由于北美拥有先进的医疗基础设施、清晰的监管环境以及较高的父母意识，预计在预测期内，北美将占据最大的市场份额。美国和加拿大拥有大型的公立和私立干细胞库，并建立了覆盖全国的采集网路。对再生医学和个人化治疗的投资正在推动该平台的扩张。医院和保险公司正在将干细胞库纳入其孕产和健康计画。领先的生物技术公司和学术研究中心的存在正在推动技术创新和标准化。

复合年增长率最高的地区：

预计亚太地区在预测期内将实现最高的复合年增长率，这主要得益于生育率、医疗保健普及率和生物银行建设等因素的共同推动。干细胞库正在印度、中国、日本和韩国等国的都市区和二线城市迅速发展。政府支持的项目正在帮助意识提升、改善基础设施并制定相关法规。当地企业正在推出价格亲民的套餐和多语言咨询服务，以覆盖不同人群。儿童和慢性病领域对样本分析和再生疗法的需求正在成长。

免费客製化服务

订阅本报告的用户可从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行市场估算、预测和复合年增长率分析（註：基于可行性检查）
  • 竞争基准化分析
    • 基于产品系列、地域覆盖和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 引言

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 原始研究资料
    • 二手研究资讯来源
    • 先决条件

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 市场机会
  • 威胁
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代产品的威胁
  • 新参与企业的威胁
  • 公司间的竞争

5. 全球干细胞库市场（依来源类型划分）

  • 脐带干细胞
  • 脐带血
  • 脐带组织
  • 胎盘
  • 成体干细胞
  • 骨髓
  • 週边血
  • 胚胎干细胞
  • 其他来源类型

6. 全球干细胞库市场（依银行类型划分）

  • 私人干细胞库
  • 公共干细胞库
  • 混合银行

7. 全球干细胞库市场按服务类型划分

  • 样本采集和运输
  • 样品处理
  • 样品分析
  • 样品储存

8. 全球干细胞库市场依用途分类

  • 已使用样品
  • 未使用的样本

9. 全球干细胞库市场（依最终用户划分）

  • 医院和专科诊所
  • 研究和学术机构
  • 製药和生物技术公司
  • 患者及其家属
  • 其他最终用户

10. 全球干细胞库市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章：主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併（M&A）
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十二章：企业概况

  • Cord Blood Registry（CBR）
  • Cryo-Cell International
  • ViaCord
  • LifeCell International
  • StemCyte
  • China Cord Blood Corporation
  • Smart Cells International
  • CryoSave
  • BioEden
  • Cells4Life
  • Global Stem Cells Group
  • StemExpress
  • Vita 34 AG
  • ReeLabs
  • Cryoviva Biotech Pvt. Ltd.
Product Code: SMRC31829

According to Stratistics MRC, the Global Stem Cell Banking Market is accounted for $11.2 billion in 2025 and is expected to reach $22.2 billion by 2032 growing at a CAGR of 10.2% during the forecast period. Stem cell banking is the process of collecting, processing, and preserving stem cells for potential future medical use. These cells, typically derived from sources such as umbilical cord blood, bone marrow, or adipose tissue, have the unique ability to develop into various cell types and regenerate damaged tissues. The preserved stem cells can be used in regenerative medicine, transplantation, and the treatment of various diseases like leukemia, lymphoma, and immune disorders. Stored in cryogenic conditions, stem cell banking provides a valuable biological resource for individuals and families, ensuring access to personalized therapies and advanced medical treatments in the future.

According to the International Society for Stem Cell Research (ISSCR), the number of ongoing clinical trials using stem cells surpassed 7,000 globally, reflecting the rapid development of regenerative therapies and the increasing demand for quality-assured stem cell storage.

Market Dynamics:

Driver:

Rising public awareness and parental demand

Families are increasingly opting to preserve umbilical cord blood and tissue for potential future use in regenerative therapies. Educational campaigns and prenatal counseling are improving understanding of stem cell applications in genetic and immune disorders. Hospitals and birthing centers are partnering with private banks to offer collection and storage services. Demand is rising across urban and semi-urban regions with growing access to maternity care. These dynamics are propelling market expansion across preventive and personalized medicine.

Restraint:

Limited proven indications

While stem cells show promise in treating blood cancers and metabolic disorders, most applications remain experimental or restricted to clinical trials. Regulatory bodies require rigorous validation before approving new therapeutic uses. Parents may hesitate to invest in banking without clear evidence of long-term benefit. Lack of standardized protocols for emerging indications slows integration into mainstream care. These limitations continue to hinder broader adoption and reimbursement support.

Opportunity:

Increased healthcare spending and private investment

Governments are funding biobanking initiatives and public-private partnerships to support regenerative medicine. Venture capital and institutional investors are backing startups focused on cryopreservation, analytics, and cell therapy integration. Expansion of fertility clinics and maternity hospitals is creating new collection points and referral networks. Demand for long-term biological storage is rising across oncology, neurology, and rare disease segments. These trends are fostering scalable and diversified growth across the stem cell banking ecosystem.

Threat:

Data privacy, consent and ethical transparency issues

Organizations must ensure secure handling of genetic and personal data linked to stored samples. Consent protocols must be clear, age-appropriate, and legally compliant across jurisdictions. Ethical concerns around commercialization, donor rights, and future use of samples require robust governance. Regulatory scrutiny is increasing across cross-border storage and research collaborations. These risks continue to constrain platform credibility and stakeholder engagement.

Covid-19 Impact:

The pandemic disrupted maternity care and elective procedures, temporarily reducing stem cell collection volumes. However, post-pandemic recovery has emphasized preventive health and biobanking as part of long-term resilience. Hospitals resumed cord blood collection and partnered with private banks to expand access. Public interest in immune health and regenerative therapies increased during the crisis. Investment in digital consent, remote counseling, and logistics improved operational continuity. These shifts are accelerating long-term integration of stem cell banking into maternal and pediatric care.

The umbilical cord stem cells segment is expected to be the largest during the forecast period

The umbilical cord stem cells segment is expected to account for the largest market share during the forecast period due to their accessibility, non-invasive collection, and broad therapeutic potential. Cord blood contains hematopoietic stem cells used in treating leukemia, anemia, and immune deficiencies. Cord tissue offers mesenchymal stem cells with applications in orthopedic and neurological conditions. Collection is safe and painless during childbirth, making it widely acceptable across cultures. Private and public banks are scaling cryopreservation and registry services for cord-derived samples. These capabilities are boosting segment dominance across clinical and research applications.

The sample analysis segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the sample analysis segment is predicted to witness the highest growth rate as banks and research institutions expand testing and characterization services. Analysis includes viability testing, HLA typing, contamination screening, and potency assays. Integration with AI and genomic platforms is enabling predictive modeling and personalized therapy planning. Demand for validated, high-quality samples is rising across clinical trials and cell therapy pipelines. Vendors are offering bundled services that combine storage with analytics and reporting. These dynamics are accelerating growth across value-added biobanking services.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced healthcare infrastructure, regulatory clarity, and high parental awareness. The United States and Canada host major private and public stem cell banks with nationwide collection networks. Investment in regenerative medicine and personalized therapies is supporting platform expansion. Hospitals and insurers are integrating stem cell banking into maternity packages and wellness plans. Presence of leading biotech firms and academic research centers is driving innovation and standardization.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as birth rates, healthcare access, and bio-banking initiatives converge. Countries like India, China, Japan, and South Korea are scaling stem cell banking across urban and tier-2 cities. Government-backed programs are supporting public awareness, infrastructure, and regulatory alignment. Local firms are launching affordable packages and multilingual counselling to reach diverse populations. Demand for sample analysis and regenerative therapies is rising across pediatric and chronic disease segments.

Key players in the market

Some of the key players in Stem Cell Banking Market include Cord Blood Registry (CBR), Cryo-Cell International, ViaCord, LifeCell International, StemCyte, China Cord Blood Corporation, Smart Cells International, CryoSave, BioEden, Cells4Life, Global Stem Cells Group, StemExpress, Vita 34 AG, ReeLabs and Cryoviva Biotech Pvt. Ltd.

Key Developments:

In July 2025, ViaCord launched its NextGen CryoPreserve(TM) platform, designed to enhance long-term viability of cord tissue stem cells. The system uses proprietary cryoprotectants and automated thawing protocols, improving therapeutic readiness for orthopedic, neurological, and autoimmune applications.

In May 2025, Cryo-Cell International partnered with Duke University's Marcus Center for Cellular Cures to advance cord blood therapies for autism and cerebral palsy. The collaboration supports FDA-regulated clinical trials and expands Cryo-Cell's therapeutic pipeline, reinforcing its leadership in translational stem cell research.

Source Types Covered:

  • Umbilical Cord Stem Cells
  • Cord Blood
  • Cord Tissue
  • Placenta
  • Adult Stem Cells
  • Bone Marrow
  • Peripheral Blood
  • Embryonic Stem Cells
  • Other Source Types

Bank Types Covered:

  • Private Stem Cell Banks
  • Public Stem Cell Banks
  • Hybrid Banks

Service Types Covered:

  • Sample Collection & Transportation
  • Sample Processing
  • Sample Analysis
  • Sample Preservation & Storage

Utilizations Covered:

  • Used Samples
  • Unused Samples

End Users Covered:

  • Hospitals & Specialty Clinics
  • Research & Academic Institutes
  • Pharmaceutical & Biotech Companies
  • Patients & Families
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Stem Cell Banking Market, By Source Type

  • 5.1 Introduction
  • 5.2 Umbilical Cord Stem Cells
  • 5.3 Cord Blood
  • 5.4 Cord Tissue
  • 5.5 Placenta
  • 5.6 Adult Stem Cells
  • 5.7 Bone Marrow
  • 5.8 Peripheral Blood
  • 5.9 Embryonic Stem Cells
  • 5.10 Other Source Types

6 Global Stem Cell Banking Market, By Bank Type

  • 6.1 Introduction
  • 6.2 Private Stem Cell Banks
  • 6.3 Public Stem Cell Banks
  • 6.4 Hybrid Banks

7 Global Stem Cell Banking Market, By Service Type

  • 7.1 Introduction
  • 7.2 Sample Collection & Transportation
  • 7.3 Sample Processing
  • 7.4 Sample Analysis
  • 7.5 Sample Preservation & Storage

8 Global Stem Cell Banking Market, By Utilization

  • 8.1 Introduction
  • 8.2 Used Samples
  • 8.3 Unused Samples

9 Global Stem Cell Banking Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Specialty Clinics
  • 9.3 Research & Academic Institutes
  • 9.4 Pharmaceutical & Biotech Companies
  • 9.5 Patients & Families
  • 9.6 Other End Users

10 Global Stem Cell Banking Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Cord Blood Registry (CBR)
  • 12.2 Cryo-Cell International
  • 12.3 ViaCord
  • 12.4 LifeCell International
  • 12.5 StemCyte
  • 12.6 China Cord Blood Corporation
  • 12.7 Smart Cells International
  • 12.8 CryoSave
  • 12.9 BioEden
  • 12.10 Cells4Life
  • 12.11 Global Stem Cells Group
  • 12.12 StemExpress
  • 12.13 Vita 34 AG
  • 12.14 ReeLabs
  • 12.15 Cryoviva Biotech Pvt. Ltd.

List of Tables

  • Table 1 Global Stem Cell Banking Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Stem Cell Banking Market Outlook, By Source Type (2024-2032) ($MN)
  • Table 3 Global Stem Cell Banking Market Outlook, By Umbilical Cord Stem Cells (2024-2032) ($MN)
  • Table 4 Global Stem Cell Banking Market Outlook, By Cord Blood (2024-2032) ($MN)
  • Table 5 Global Stem Cell Banking Market Outlook, By Cord Tissue (2024-2032) ($MN)
  • Table 6 Global Stem Cell Banking Market Outlook, By Placenta (2024-2032) ($MN)
  • Table 7 Global Stem Cell Banking Market Outlook, By Adult Stem Cells (2024-2032) ($MN)
  • Table 8 Global Stem Cell Banking Market Outlook, By Bone Marrow (2024-2032) ($MN)
  • Table 9 Global Stem Cell Banking Market Outlook, By Peripheral Blood (2024-2032) ($MN)
  • Table 10 Global Stem Cell Banking Market Outlook, By Embryonic Stem Cells (2024-2032) ($MN)
  • Table 11 Global Stem Cell Banking Market Outlook, By Other Source Types (2024-2032) ($MN)
  • Table 12 Global Stem Cell Banking Market Outlook, By Bank Type (2024-2032) ($MN)
  • Table 13 Global Stem Cell Banking Market Outlook, By Private Stem Cell Banks (2024-2032) ($MN)
  • Table 14 Global Stem Cell Banking Market Outlook, By Public Stem Cell Banks (2024-2032) ($MN)
  • Table 15 Global Stem Cell Banking Market Outlook, By Hybrid Banks (2024-2032) ($MN)
  • Table 16 Global Stem Cell Banking Market Outlook, By Service Type (2024-2032) ($MN)
  • Table 17 Global Stem Cell Banking Market Outlook, By Sample Collection & Transportation (2024-2032) ($MN)
  • Table 18 Global Stem Cell Banking Market Outlook, By Sample Processing (2024-2032) ($MN)
  • Table 19 Global Stem Cell Banking Market Outlook, By Sample Analysis (2024-2032) ($MN)
  • Table 20 Global Stem Cell Banking Market Outlook, By Sample Preservation & Storage (2024-2032) ($MN)
  • Table 21 Global Stem Cell Banking Market Outlook, By Utilization (2024-2032) ($MN)
  • Table 22 Global Stem Cell Banking Market Outlook, By Used Samples (2024-2032) ($MN)
  • Table 23 Global Stem Cell Banking Market Outlook, By Unused Samples (2024-2032) ($MN)
  • Table 24 Global Stem Cell Banking Market Outlook, By End User (2024-2032) ($MN)
  • Table 25 Global Stem Cell Banking Market Outlook, By Hospitals & Specialty Clinics (2024-2032) ($MN)
  • Table 26 Global Stem Cell Banking Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
  • Table 27 Global Stem Cell Banking Market Outlook, By Pharmaceutical & Biotech Companies (2024-2032) ($MN)
  • Table 28 Global Stem Cell Banking Market Outlook, By Patients & Families (2024-2032) ($MN)
  • Table 29 Global Stem Cell Banking Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.